The emergence of antibiotic-resistant infections has intensified interest in phage therapy, but a new mechanism of bacterial evasion could complicate treatment strategies for one of medicine's most challenging pathogens. Mycobacterium abscessus, responsible for severe lung infections particularly difficult to treat, can rapidly switch its cellular architecture to escape therapeutic viruses.
Researchers discovered that M. abscessus smooth variants—the predominant form in Asian populations—can transform into rough variants when exposed to bacteriophages. This morphotype switching occurs through mutations in the glycopeptidolipid (GPL) biosynthetic pathway, fundamentally altering the bacterial cell surface. The transformation renders previously effective phages ineffective, creating treatment-resistant populations both in laboratory cultures and animal models. The switching mechanism represents a sophisticated bacterial defense that occurs within the timeframe of potential clinical treatment.
This finding carries significant implications for the development of phage therapeutics, an increasingly important alternative as traditional antibiotics fail against multidrug-resistant pathogens. The research suggests that single-phage treatments may inadvertently select for resistant variants, potentially worsening patient outcomes. However, the study also demonstrates that carefully designed phage combinations targeting both morphotypes can overcome this resistance mechanism.
The discovery highlights a critical gap in current phage therapy development, which has largely focused on rough variants despite smooth variants being more clinically relevant in many regions. For personalized medicine approaches, this suggests the need for morphotype-specific diagnostic testing and tailored phage cocktail design. The work underscores that successful phage therapy will require understanding bacterial evolution under therapeutic pressure, not just initial susceptibility patterns.